The Value of Determination of Nuclear Oestrogen Receptors in Breast Cancer Biopsies

  • S. Cowan
  • C. Love
  • R. E. Leake
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 91)

Abstract

The oestrogen receptor status of the soluble fraction of a tumour biopsy is now accepted as a valuable tool in the management of advanced breast cancer [11]. Soluble receptor status of primary disease may also be of value as a prognostic index [3, 20], although this value might be limited to patients with intermediate nodal involvement [19]. However, the presence of soluble receptors alone is not an absolute index of hormonal dependence [22]. Hormone-receptor complex might fail to undergo translocation/activation [37] or to bind to the correct acceptor sites on the DNA [33]. Loss of hormonal dependence through a breakdown at the post-transcriptional level is also a possibility. For these reasons several parameters of oestrogen response have been studied in breast tumour biopsies. Measurement of the presence of progesterone receptor (a product of oestrogen action) has proved productive [11]. The suggestion that a useful index of hormonal dependence might simply be the presence of nuclear-bound oestrogen receptor [21] has been followed up by several groups [2, 15, 29, 38].

Keywords

Sucrose Glycerol Estrogen EDTA Fluoride 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anderson JN, Clark JH, Peck EJ Jr (1972) Oestrogen and nuclear binding sites: determination of specific sites by [3H] oestradiol exchange. Biochem J 126: 561–567PubMedGoogle Scholar
  2. 2.
    Barnes DM, Skinner LG, Ribeiro GG (1979) Triple hormone-receptor assay: a more accurate predictive tool for the treatment of advanced breast cancer? Br J Cancer 40: 862–865PubMedCrossRefGoogle Scholar
  3. 3.
    Bishop HM, Blarney RW, Elston CW, Haybittle JL, Nicholson RI, Griffiths K (1979) Relationship of oestrogen-receptor status to survival in breast cancer. Lancet 2: 283–284PubMedCrossRefGoogle Scholar
  4. 4.
    Blankenstein MA, Peters-Mechielsen MJ, Mulder E, Van Der Molen HJ (1980) Estimation of total oestrogen receptors in DMB A-induced rat mammary tumors by exchange of nuclear bound ligand at low temperature; a comparison with rat uterus. J Steroid Biochem 13: 557–564PubMedCrossRefGoogle Scholar
  5. 5.
    British Breast Group (1974) Assessment of response to treatment in advanced breast cancer. Lancet 2: 38–39CrossRefGoogle Scholar
  6. 6.
    Castagnetta L, Lo Casto M, Mercadante T, Polito L, Cowan S, Leake RE (1983) Intratumoural variation of oestrogen receptor status in endometrial cancer. Br J Cancer 47: 261–267PubMedCrossRefGoogle Scholar
  7. 7.
    Chamness GC, McGuire WL (1980) Methods for analyzing steroid receptors in human breast cancer. In: McGuire WL (ed) Breast cancer, vol 3. Plenum Medical, New York, p 149Google Scholar
  8. 8.
    Clark JH, Peck EJ Jr (1976) Nuclear retention of receptor-oestrogen complex and nuclear acceptor sites. Nature 260: 635–637PubMedCrossRefGoogle Scholar
  9. 9.
    Delarue JC, Bohoun C (1980) Utilization of the measurement of hormone receptors in the treatment of breast cancer in women. Ann Biol Clin (Paris) 38: 293–296Google Scholar
  10. 10.
    Duffy MJ, O’Connell M (1981) Estrogens, estradiol receptors and peroxidase activity in human mammary carcinomas. Eur J Cancer 17: 711–716PubMedCrossRefGoogle Scholar
  11. 11.
    Edwards DP, Chamness GC, McGuire WL (1979) Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta 560: 457–486PubMedGoogle Scholar
  12. 12.
    Edwards DP, Martin PM, Horwitz KB, Chamness GC, McGuire WL (1980) Subcellular compartmentalization of estrogen receptors in human breast cancer cells. Exp Cell Res 127: 197–213PubMedCrossRefGoogle Scholar
  13. 13.
    Fazekas AG, MacFarlane JK (1980) Studies on cytosol and nuclear binding of estradiol in human breast cancer. J Steroid Biochem 13: 613–622PubMedCrossRefGoogle Scholar
  14. 14.
    Garola RE, McGuire WL (1977) An improved assay for nuclear oestrogen receptor in experimental and human breast cancer. Cancer Res 37: 3333–3337PubMedGoogle Scholar
  15. 15.
    Hahnel R, Partridge RK, Gavet L, Twaddle E, Ratajczak T (1980) Nuclear and cytoplasmic estrogen receptors and progesterone receptors in breast cancer. Eur J Cancer 16: 1027–1033PubMedCrossRefGoogle Scholar
  16. 16.
    Hawkins RA, Roberts MM, Forrest APM (1980) Oestrogen receptors and breast cancer: current status. Br J Surg 67: 152–169CrossRefGoogle Scholar
  17. 17.
    Hayward JL, Carbonne PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89–94CrossRefGoogle Scholar
  18. 18.
    Horwitz KB, McGuire WL (1980) Nuclear estrogen receptors: effect of inhibitors on processing and steady state levels. J Biol Chem 255: 9699–9705PubMedGoogle Scholar
  19. 19.
    Howat JMT, Barnes DM (1981) Oestrogen receptor status and management of breast cancer. Lancet 1: 1317PubMedCrossRefGoogle Scholar
  20. 20.
    Knight WA, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669–4671PubMedGoogle Scholar
  21. 21.
    Laing L, Smith MG, Caiman KC, Smith DC, Leake RE (1977) Nuclear oestrogen receptors and treatment of breast cancer. Lancet 2: 168–169PubMedCrossRefGoogle Scholar
  22. 22.
    Leake RE (1976) Current views on oestrogen receptors. Trends Biochem Sci 1: 137–139Google Scholar
  23. 23.
    Leake RE, Laing L, Smith DC (1979) A role for nuclear oestrogen receptors in prediction of therapy regime for breast cancer patients. In: King RJB (ed) Steroid receptor assays in human breast tumours. Alpha Omega, Cardiff, p 73Google Scholar
  24. 24.
    Leake RE (1980) Methodology of steroid hormone receptor determination in breast cancer. In: Taylor RW (ed) Progestogens in the management of hormonal responsive carcinomas. Medicine Publishing Foundation, Oxford, p 3Google Scholar
  25. 25.
    Leake RE, Laing L, Caiman KC, Macbeth FR, Crawford D, Smith DC (1981) Oestrogen-re¬ceptor status and endocrine therapy of breast cancer: response rates and status stability. Br J Cancer 43: 59–66PubMedCrossRefGoogle Scholar
  26. 26.
    Leake RE, Laing L, McArdle C, Smith DC (1981) Soluble and nuclear oestrogen receptor status in human breast cancer in relation to prognosis. Br J Cancer 43: 67–71PubMedCrossRefGoogle Scholar
  27. 27.
    MacFarlane JK, Fleiszer D, Fazekas AG (1980) Studies on estrogen receptors and regression in human breast cancer. Cancer 45: 2998–3003PubMedCrossRefGoogle Scholar
  28. 28.
    Osborne CK, Yochmowitz MG, Knight WA, McGuire WL (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888PubMedCrossRefGoogle Scholar
  29. 29.
    Panko WB, MacLeod RM (1978) Uncharged nuclear receptors for estrogen in breast cancers. Cancer Res 38: 1948–1951PubMedGoogle Scholar
  30. 30.
    Paridaens R, Sylvester RJ, Ferrazzi E, Legros N, Leclercq G, Heuson JC (1980) Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 46: 2889–2895PubMedCrossRefGoogle Scholar
  31. 31.
    Ruh TS, Baudendistel LJ (1977) Different nuclear binding sites for antiestrogen and estrogen receptor complexes. Endocrinology 100: 420–426PubMedCrossRefGoogle Scholar
  32. 32.
    Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R (1981) Estrogen receptor: a prognostic factor in breast cancer. Cancer 47: 554–560PubMedCrossRefGoogle Scholar
  33. 33.
    Sato B, Nomura Y, Nakao K, Ochi H, Matsumoto K (1981) DNA binding ability of estrogen receptor from human breast cancer. J Steroid Biochem 14: 295–303PubMedCrossRefGoogle Scholar
  34. 34.
    Schoenberg DR, Clark JK (1980) A simple modification of the estrogen receptor exchange assay: validation in nuclei from the rat uterus and a mouse mammary tumor. Endocrinology 106: 56–60PubMedCrossRefGoogle Scholar
  35. 35.
    Silfversward C, Skoog L, Humla S, Gustafsson SA, Nordenskjold B (1980) Intratumoral variation of cytoplasmic and nuclear estrogen receptor concentrations in human mammary carcinoma. Eur J Cancer 16: 59–63PubMedCrossRefGoogle Scholar
  36. 36.
    Taylor RN, Swaneck GE, Smith RG (1980) Correlation of nuclear acceptor sites for oestrogen receptors with gene transcription in vitro. Biochem J 192: 385–393PubMedGoogle Scholar
  37. 37.
    Thorsen T, Stoa KF (1979) Nuclear uptake of oestradiol-17/3 in human mammary tumour tissue. J Steroid Biochem 10: 595–599PubMedGoogle Scholar
  38. 38.
    Thorsen T (1980) Occupied and unoccupied oestradiol receptor in human breast tumour cytosol. J Steroid Biochem 13: 405–408PubMedCrossRefGoogle Scholar
  39. 39.
    Tilley WD, Keightley DD, Cant ELM (1978) Inter-site variation of oestrogen receptors in human breast cancers. Br J Cancer 38: 544–546PubMedCrossRefGoogle Scholar
  40. 40.
    Tisdale MJ (1977) Inhibition of prostaglandin synthetase by anti-tumour agents. Chem Biol Interact 18: 91–102PubMedCrossRefGoogle Scholar
  41. 41.
    Zava DT, Harrington NY, McGuire WL (1976) Nuclear estradiol receptor in the adult rat uterus: a new exchange assay. Biochemistry 15: 4292–4297PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1984

Authors and Affiliations

  • S. Cowan
    • 1
  • C. Love
    • 1
  • R. E. Leake
    • 1
  1. 1.Department of BiochemistryUniversity of GlasgowGlasgowUK

Personalised recommendations